Skip to content
Partnerships
News
Contact
Fore Biotherapeutics
Pipeline
Science
Plixorafenib Program
Publications
Patients
Our Science Explained
Clinical Trials
Forte Trial
Expanded Access
Company
About Us
People
Leadership
Investors
Careers
Governance
Search
Pipeline
Science
Plixorafenib Program
Publications
Patients
Our Science Explained
Clinical Trials
Forte Trial
Expanded Access
Company
About Us
People
Leadership
Investors
Careers
Governance
Partnerships
News
Contact
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor
July 29, 2016 1:07 PM EDT